SANA vs. NVAX, DNA, BEAM, FUSN, CGON, INBX, VCYT, ADMA, HRMY, and KYMR
Should you be buying Sana Biotechnology stock or one of its competitors? The main competitors of Sana Biotechnology include Novavax (NVAX), Ginkgo Bioworks (DNA), Beam Therapeutics (BEAM), Fusion Pharmaceuticals (FUSN), CG Oncology (CGON), Inhibrx (INBX), Veracyte (VCYT), ADMA Biologics (ADMA), Harmony Biosciences (HRMY), and Kymera Therapeutics (KYMR). These companies are all part of the "medical" sector.
Novavax (NASDAQ:NVAX) and Sana Biotechnology (NASDAQ:SANA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, community ranking, media sentiment and dividends.
Novavax has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500. Comparatively, Sana Biotechnology has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500.
Sana Biotechnology has a net margin of 0.00% compared to Sana Biotechnology's net margin of -40.01%. Sana Biotechnology's return on equity of 0.00% beat Novavax's return on equity.
In the previous week, Novavax had 36 more articles in the media than Sana Biotechnology. MarketBeat recorded 40 mentions for Novavax and 4 mentions for Sana Biotechnology. Sana Biotechnology's average media sentiment score of 0.52 beat Novavax's score of 0.46 indicating that Novavax is being referred to more favorably in the media.
Sana Biotechnology has lower revenue, but higher earnings than Novavax. Sana Biotechnology is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.
Novavax received 830 more outperform votes than Sana Biotechnology when rated by MarketBeat users. Likewise, 74.12% of users gave Novavax an outperform vote while only 50.00% of users gave Sana Biotechnology an outperform vote.
53.0% of Novavax shares are held by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are held by institutional investors. 0.9% of Novavax shares are held by company insiders. Comparatively, 34.9% of Sana Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Novavax presently has a consensus price target of $14.00, suggesting a potential upside of 7.61%. Sana Biotechnology has a consensus price target of $11.67, suggesting a potential upside of 33.64%. Given Novavax's stronger consensus rating and higher possible upside, analysts clearly believe Sana Biotechnology is more favorable than Novavax.
Summary
Novavax beats Sana Biotechnology on 9 of the 17 factors compared between the two stocks.
Get Sana Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for SANA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SANA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sana Biotechnology Competitors List
Related Companies and Tools
